Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)

Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy’s heterogeneous nature, treatment is individualized based on the patient’s seizure syndrome and type. The market remains largely genericized, with antiepileptic drugs (AEDs) often used in combination to control refractory seizures. Although second-generation AEDs continue to lead the market, high-priced third-generation AEDs such as cenobamate, fenfluramine, and ganaxolone continue to gain traction in underserved and orphan epilepsy populations. This report assesses the market potential of late-phase therapies such as Xenon’s azetukalner, SK Biopharmaceuticals’ carisbamate, and Lundbeck’s bexicaserin for difficult-to-treat and orphan epilepsies and provides a detailed profile of the emerging disease-modifying treatment zorevunersen (Biogen / Stoke), a gene therapy in Phase 3 development for Dravet syndrome. Our forecast also includes an assessment of outpatient rescue therapies, including Engage’s Staccato alprazolam.

Questions answered

• How does the epilepsy market differ by region, and how is it expected to evolve in the near future?
• What market dynamics and competitive strategies will determine the success of new and existing AEDs in an increasingly genericized landscape?
• What are the challenges in treating drug-resistant epilepsy, and how are emerging therapies addressing this critical unmet need?
• How will the adoption of novel disease-modifying therapies, such as gene therapies, impact the epilepsy treatment landscape?

Geography: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading neurologists and epileptologists. Survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of epilepsy by country.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key epilepsy therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.